Oncology Business Management | Specialty

TRK Inhibition: Future Challenges and Evolutions

July 30th 2019

Use of TRK Inhibition in Specific Tumor Types

July 30th 2019

The Importance and Evolution of NGS Testing

July 30th 2019

Envisioning Use of TRK Inhibitors in Clinical Practice

July 30th 2019

Other Approaches to TRK-Fusion Cancers

July 30th 2019

TRK Inhibition in CNS Tumors or Metastases

July 30th 2019

Treating Pediatric Patients With TRK Inhibitors

July 30th 2019

Considering Available Data for Entrectinib

July 30th 2019

TRK Inhibition: Personal Experience With Larotrectinib

July 30th 2019

Larotrectinib for NTRK Fusions: Patient Selection

July 30th 2019

Updated Data for Larotrectinib

July 30th 2019

Larotrectinib: The First FDA-Approved TRK Inhibitor

July 30th 2019

NTRK: An Attractive Target for Therapy

July 30th 2019

Control Arms Must Be Selected for Meaningful Comparison

July 24th 2019

Although concerns have been raised in recent years regarding the need for randomized trials to augment the body of clinical understanding, one critical issue that has failed to generate sufficient discussion is how the choice of the control arm affects the interpretation of an individual study’s outcome and potentially undermines the ethical basis for that particular study.

Statistics Show Increase in US Cancer Survivors

July 20th 2019

The growth and aging of the population combined with advances in the early detection and treatment of cancer have resulted in a growing population of survivors across the nation, according to a study from the American Cancer Society and the National Cancer Institute.

Report Highlights Struggle to Help Survivors Prepare for Life After Treatment

July 19th 2019

A strong unmet need for survivorship care plans exists in the cancer treatment community and better follow-up is required for patients who have moved on from treatment and are experiencing its aftereffects.

CMS Unveils Proposed Radiation Oncology Model of Care

July 18th 2019

Until now, radiation oncology (RO) has remained largely untouched by the valuebased initiatives of the Centers for Medicare and Medicaid Services. The federal agency aims to change that with a proposed RO Model of care that would promote site-neutral payment and take away incentives for volume-based billing.

Dr. Norden on Differences Between mCODE and Cota's CNA Network

July 16th 2019

Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses differences between mCODE and Cota’s CNA Network.

Open-Access Publishing Model May Introduce New Biases in Oncology

July 15th 2019

For clinical science, particularly oncology, there has never been a more exciting era than today.

Oncology Practices Can Preserve Independence With a Strong Marketing Effort

June 29th 2019

From 2016 to 2018, there was an 8% increase in the number of community oncology practices consolidated into hospital systems, and this trend has many independent practices struggling to avoid the same fate. Two winning strategies are emerging to help practices remain independent.